Literature DB >> 15165915

Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.

Robert P Giugliano1, Marc S Sabatine, C Michael Gibson, Matthew T Roe, Robert A Harrington, Sabina A Murphy, David A Morrow, Elliott M Antman, Eugene Braunwald.   

Abstract

The restoration of epicardial and myocardial flow remains the primary goal of reperfusion therapy in patients with ST-segment elevation myocardial infarction, but the optimal method to assess this goal has not been defined. Thrombolysis In Myocardial Infarction flow grade (TFG), myocardial perfusion grade (MPG), and ST-segment resolution (STRes) were combined to formulate a new measure of successful reperfusion in 649 patients who received pharmacologic reperfusion therapy in 3 recent phase II clinical trials of ST-segment elevation myocardial infarction. Coronary angiograms and electrocardiograms were analyzed at 60 minutes (before any intervention) after the initiation of reperfusion therapy. The complete restoration of perfusion, or the "trifecta," defined as the presence of TFG 3, MPG 3, and complete (> or =70%) STRes, occurred in 117 patients (18%). The achievement of this trifecta was associated with low rates of 30-day mortality (0% vs 3.9%, p = 0.02), congestive heart failure (CHF) (0.9% vs 7.1%, p = 0.01), and the combination of death or CHF (0.9% vs 10.7%, p = 0.001). When the results were stratified with respect to subsequent percutaneous coronary intervention (PCI) from 60 to 120 minutes, attainment of the trifecta at 60 minutes remained a strong predictor of better clinical outcomes, particularly in those patients who underwent early PCI. The achievement of TFG 3, MPG 3, and complete STRes at 60 minutes after fibrinolytic therapy and before PCI occurred in only 18% of patients but was associated with very low rates of death and CHF at 30 days. This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165915     DOI: 10.1016/j.amjcard.2004.02.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.

Authors:  Larisa Renata Pantea-Roșan; Simona Gabriela Bungau; Andrei-Flavius Radu; Vlad Alin Pantea; Mădălina Ioana Moisi; Cosmin Mihai Vesa; Tapan Behl; Aurelia Cristina Nechifor; Elena Emilia Babes; Manuela Stoicescu; Daniela Gitea; Diana Carina Iovanovici; Cristiana Bustea
Journal:  Diagnostics (Basel)       Date:  2022-04-08

2.  Contrast echocardiography accurately predicts myocardial perfusion before angiography during acute myocardial infarction.

Authors:  Gregory B Schnell; Albert J Kryski; Luana Mann; Todd J Anderson; Israel Belenkie
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

Review 3.  Systematic review of fibrinolytic-facilitated percutaneous coronary intervention: potential benefits and future challenges.

Authors:  J Afilalo; A Michael Roy; M J Eisenberg
Journal:  Can J Cardiol       Date:  2009-03       Impact factor: 5.223

4.  Comparison of different methods of ST segment resolution analysis for prediction of 1-year mortality after primary angioplasty for acute myocardial infarction.

Authors:  Jakub Przyluski; Maciej Karcz; Lukasz Kalińczuk; Mariusz Kruk; Jerzy Pregowski; Edyta Kaczmarska; Joanna Petryka; Paweł Bekta; Tomasz Deptuch; Cezary Kepka; Adam Witkowski; Witold Ruzyllo
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-01       Impact factor: 1.468

5.  Factors Contributing to Door-to-Balloon Times of ≤90 Minutes in 97% of Patients with ST-Elevation Myocardial Infarction: Our One-Year Experience with a Heart Alert Protocol.

Authors:  Joel T Levis; Mary P Mercer; Mark Thanassi; James Lin
Journal:  Perm J       Date:  2010

6.  In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study.

Authors:  Igor Matos Lago; Gustavo Caires Novaes; André Vannucchi Badran; Rafael Brolio Pavão; Ricardo Barbosa; Geraldo Luiz de Figueiredo; Moysés de Oliveira Lima; Jorge Luiz Haddad; André Schmidt; José Antônio Marin
Journal:  Arq Bras Cardiol       Date:  2016-11       Impact factor: 2.000

Review 7.  Role of no reflow and microvascular obstruction in the prognostic stratification of STEMI patients.

Authors:  Alessandro Durante
Journal:  Anatol J Cardiol       Date:  2018-03-13       Impact factor: 1.596

Review 8.  No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction.

Authors:  Sanjiv Gupta; Madan Mohan Gupta
Journal:  Indian Heart J       Date:  2016-04-19

9.  Assessment of the relationship between reperfusion success and T-peak to T-end interval in patients with ST elevation myocardial infarction treated with percutaneous coronary intervention.

Authors:  Metin Çağdaş; Süleyman Karakoyun; İbrahim Rencüzoğulları; Yavuz Karabağ; Mahmut Yesin; Yalçın Velibey; İnanç Artaç; Doğan İliş; Süleyman Çağan Efe; Onur Taşar; Halil İbrahim Tanboğa
Journal:  Anatol J Cardiol       Date:  2018-01       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.